Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1 July 2024
| Author | Lambach, Philipp |
| Author | Silal, Sheetal |
| Author | Sbarra, Alyssa N. |
| Author | Crowcroft, Natasha S. |
| Author | Frey, Kurt |
| Author | Ferrari, Matt |
| Author | Vynnycky, Emilia |
| Author | Metcalf, C. Jessica E. |
| Author | Winter, Amy K. |
| Author | Zimmerman, Laura |
| Author | Koh, Mitsuki |
| Author | Sheel, Meru |
| Author | Kim, Sun-Young |
| Author | Munywoki, Patrick K. |
| Author | Portnoy, Allison |
| Author | Aggarwal, Rakesh |
| Author | Farooqui, Habib Hasan |
| Author | Flasche, Stefan |
| Author | Hogan, Alexandra B. |
| Author | Leung, Kathy |
| Author | Moss, William J. |
| Author | Wang, Xuan-Yi |
| Available date | 2024-11-20T06:03:03Z |
| Publication Date | 2024 |
| Publication Name | Vaccine |
| Resource | Scopus |
| Identifier | http://dx.doi.org/10.1016/j.vaccine.2024.126307 |
| ISSN | 0264410X |
| Abstract | The World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) serves to independently review and evaluate vaccine-related research to maximize the potential impact of vaccination programs. From 28 June - 1 July 2024, IVIR-AC was convened for an ad hoc meeting to discuss new evidence on criteria for rubella vaccine introduction and the risk of congenital rubella syndrome. This report summarizes background information on rubella virus transmission and the burden of congenital rubella syndrome, meeting structure and presentations, proceedings, and recommendations. |
| Sponsor | P. L. was supported by the Bill & Melinda Gates Foundation for this work. S. S. was supported by the World Health Organization for this work. A. N. S. was financially supported by the World Health Organization for this work, and is additionally supported by the Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, and the National Institutes of Health. K. F. is employed by the Bill & Melinda Gates Foundation. M. F. is supported by the National Science Foundation, the Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, Centers for Disease Control and Prevention, and Imperial College London. E. V. was supported for this work by Gavi, the Vaccine Alliance via the Vaccine Impact Modeling Consortium (VIMC), which is jointly funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation. C. J. E. M. has previously received travel funds to visit the Max Plank Institute of Evolutionary Anthropology. A. K. W. was supported for this work by Gavi, the Vaccine Alliance, is additionally supported by the Bill & Melinda Gates Foundation, and has previously received travel funds from Gavi, the Vaccine Alliance. M. K. was supported for this work by the Bill & Melinda Gates Foundation. A. P. is supported by Gavi, the Vaccine Alliance, Imperial College London, the Bill & Melinda Gates Foundation, and the World Health Organization. A. B. H. was supported by the Australian National Health and Medical Research Council for this work, is additionally supported by the Australian NSW Ministry of Health, PATH, the World Health Organization, and Gavi, the Vaccine Alliance, and has received consulting fees from the Australian NSW Ministry of Health, WHO Europe and Asian Development Bank. A. N. S. and M. F. report travel related support from the World Health Organization to attend previous IVIR-AC meetings. All other authors have no declarations. |
| Language | en |
| Publisher | Elsevier |
| Subject | Congenital rubella syndrome IVIR-AC RCV Rubella |
| Type | Conference Paper |
| Issue Number | 26 |
| Volume Number | 42 |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1508 items ]